MedTrace Logo

Dose-dependent Effects of Oxytocin on the Amygdala and Reward System

NCT03846739 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2019-02-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether effects of intranasal oxytocin on amygdala and reward system responses vary as a function of treatment dose in women in comparison to men.

Conditions

  • Healthy

Interventions

DRUG

Oxytocin nasal spray

Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.

DRUG

Placebo

The placebo nasal sprays contain identical ingredients except for the peptide itself.

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Rene Hurlemann, MD, PhD · University of Bonn

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-03
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846739 on ClinicalTrials.gov